VCELVericel Corporation

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M+5.8% YoY

Gross Profit

$22M69.7% margin

Operating Income

$4M10.9% margin

Net Income

$4M11.2% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

+61.2%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$4M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$158M

Total Liabilities

$43M

Stockholders' Equity

$115M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$30M	+5.8%
Gross Profit	$22M	$21M	+6.1%
Operating Income	$4M	$3M	+13.6%
Net Income	$4M	$3M	+4.3%

Revenue Segments

MACI Implants and Kits, and Epicel

$31M100%

VCEL Q3 2020 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena